Loading
NKT3964 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for CCNE1-amplified endometrial and ovarian cancer.
NKT3964 is a small molecule PROTAC degrader, oral from NiKang Therapeutics. A selective degrader of CDK2, a cell-cycle enzyme that cancers with extra copies of the CCNE1 gene rely on. The phase 1 study NCT06586957 is recruiting; the company says it is now enrolling people with CCNE1-amplified endometrial cancer. Whether it works in people has not been established.
A selective degrader of CDK2, a cell-cycle enzyme that cancers with extra copies of the CCNE1 gene rely on. Connects to CDK2.
1.NKT3964 binds CDK2 with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NKT3964" OR ABSTRACT:"NKT3964") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKT3964, not a curated reading list.
Shares CDK2, NiKang Therapeutics and the tag pipeline.
Shares CDK2, Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/